Hutchison China Meditech Ltd. (Chi-Med) has scored the first approval in China of a fully domestically developed anticancer drug, with a nod for Elunate (fruquintinib) from the country's newly renamed National Medical Products Administration of China (NMPA, formerly CFDA).
The oral, highly selective small molecule inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 is indicated for...








